Evidence map›Paper›PMID 39371748›Full record

ArticleCureus2024

Adaptive Stereotactic Body Radiation Therapy in the Management of Oligometastatic Uterine Leiomyosarcoma: A Clinical Case Report.

Maryanne J Lubas, Joseph Panetta, Robert Freeman, Joshua E Meyer

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maryanne J LubasDepartment of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA.
Joseph PanettaDepartment of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA.
Robert FreemanDepartment of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA.
Joshua E MeyerDepartment of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Safe delivery of stereotactic body radiation therapy (SBRT) to large (>5 cm) oligometastatic abdominopelvic tumors can often be challenging, especially in tumors that require a higher biologically effective dose (BED) for tumor control. Adaptive stereotactic body radiation therapy (A-SBRT) involves inter-fraction and real-time replanning while the patient is on the treatment table, potentially allowing for improved dose coverage and greater sparing of critical structures. Our case report illustrates the benefit of CT-based A-SBRT in the treatment and management of an oligometastatic uterine leiomyosarcoma patient with a rapidly enlarging pelvic recurrence. A 60-year-old female presented to the radiation oncology clinic for treatment of an enlarging, right pelvic oligometastatic leiomyosarcoma. She was prescribed 35 Gy in five fractions. Planning prioritized the sparing of nearby small bowels while maximizing coverage of the planning target volume (PTV). On treatment day, two plans were calculated, the initial plan recalculated on the current CBCT (scheduled plan) and a plan reoptimized using current contours (adapted plan), and the more appropriate one was chosen for delivery. The adapted plan was chosen for all five fractions, with the adapted plan offering better small bowel sparing in five fractions and better target coverage in four fractions, delivering a total of 34 Gy to 95% of the PTV while limiting the small bowel to a maximum point dose of 37 Gy. At approximately six months out from treatment, the patient showed continued radiographic response and resolved acute Grade 1 gastrointestinal toxicity. This case study therefore demonstrates the successful treatment of a large oligometastatic abdominopelvic tumor using CT-based A-SBRT and builds on previous experience treating abdominal cases adaptively.

Indexed as

adaptive radiation therapycbct-dosimetryendometrial cancersrecurrent leiomyosarcomastereotactic body radiotherapy (sbrt)

Identifiers

PMID39371748
PMCPMC11452315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.